nogalamycin and Colonic-Neoplasms

We estimated antitumor activity of TUT-7 following p.o. administration using animal tumor models and human tumor xenografts. In mouse L 1210 leukemia system, antitumor activity of TUT-7 administered orally was as good as that by i.v. administration. Treatment involving schedules of every 4-days or daily administration was much more effective than single treatment. Therapiotic indices of this compound administered both p.o. or i.v. routes, were better than that of adriamycin administered i.v.. TUT-7 showed antitumor activities against various mouse tumors (L 1210 leukemia, P 388 leukemia, colon 38 adenocarcinoma, B 16 melanoma), LX-1 human tumor xenografts, and Yoshida sarcoma in rat. Base on above results, we concluded that oral administration is one of the useful route of TUT-7 administration.

Topics: Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Daunorubicin; Doxorubicin; Humans; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Lung Neoplasms; Menogaril; Mice; Nogalamycin; Rats; Sarcoma, Yoshida

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Male; Menogaril; Middle Aged; Nogalamycin; Rectal Neoplasms